Literature DB >> 25113065

Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery.

J C Gill1, P M Mannucci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25113065     DOI： 10.1111/hae.12498

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  6 in total

1.  Effectiveness and safety of hFVIII/VWF concentrate (Voncento®) in patients with inherited von Willebrand disease requiring surgical procedures: the OPALE multicentre observational study.

Authors:  Lucia Rugeri; Roseline d'Oiron; Annie Harroche; Valérie Proulle; Guillaume Mourey; Emmanuelle De Raucourt; Dominique Desprez; Nathalie Itzhar Baikian; Brigitte Pan Petesch; Annie Borel-Derlon; Sophie Combe; Birgit Frotscher; Abel Hassoun; Hasan Catovic; Diane Bracquart; Marc Trossaërt
Journal:  Blood Transfus       Date:  2020-11-27       Impact factor: 3.443

2.  Evidence-Based Minireview: Perioperative management of the VWD patient at elevated thrombotic risk.

Authors:  Holleh D Husseinzadeh; Sandra Haberichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study.

Authors:  Jenny Goudemand; Françoise Bridey; Ségolène Claeyssens; Nathalie Itzhar-Baïkian; Annie Harroche; Dominique Desprez; Claude Négrier; Pierre Chamouni; Hervé Chambost; Céline Henriet; Sophie Susen; Annie Borel-Derlon
Journal:  J Thromb Haemost       Date:  2020-06-25       Impact factor: 5.824

4.  Sixth Åland Island Conference on von Willebrand disease.

Authors:  Erik Berntorp; Sonata S Trakymienė; Augusto B Federici; Katharina Holstein; Fernando F Corrales-Medina; Glenn F Pierce; Alok Srivastava; Mario von Depka Prondzinski; Jill M Johnsen; Irena P Zupan; Susan Halimeh; Vuokko Nummi; Jonathan C Roberts
Journal:  Haemophilia       Date:  2022-07       Impact factor: 4.263

5.  Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Authors:  F Peyvandi; A Mamaev; J-D Wang; O Stasyshyn; M Timofeeva; N Curry; A R Cid; T T Yee; K Kavakli; G Castaman; A Sytkowski
Journal:  J Thromb Haemost       Date:  2018-12-20       Impact factor: 5.824

6.  In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor.

Authors:  Meaghan E Colling; Kenneth D Friedman; Walter H Dzik
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.